CEA (Carcinoembryonic Antigen): Colorectal Cancer Surveillance, Not Screening

CEA is a family of glycoproteins that act as cell adhesion molecules. They show up during fetal gut development, get suppressed in healthy adult epithelium, and reappear in adenocarcinomas of the colon, rectum, stomach, pancreas, lung, breast, and elsewhere. CEA is shed into blood and other body fluids when produced. The "carcinoembryonic" name reflects the original observation: it appears in fetal tissue, mostly disappears, then comes back in cancer.

Roughly 70 to 80 percent of colorectal cancers express CEA. Only about 30 to 40 percent of stage I disease has CEA above the laboratory cutoff. That insensitivity at the curable stage is exactly why CEA fails as a screening test. It detects advanced disease better than early disease, which is the opposite of what a screening test needs.

The molecule is also produced in benign tissues during inflammation, hepatic dysfunction, and chronic injury, which explains the long list of benign causes of mild elevation.

Reference ranges differ by smoking status:

• Non-smokers: below 3.0 ng/mL.
• Smokers: below 5.0 ng/mL. Chronic smoking shifts the entire baseline upward.
• 3 to 10 ng/mL in non-smokers: mild elevation. Most are benign (smoking, recent inflammation, hepatic dysfunction). In someone without colorectal cancer history, this value alone is not actionable without context.
• 10 to 20 ng/mL: moderate elevation. Worth investigating with imaging if not explained by smoking or recent inflammation.
• Above 20 ng/mL: high probability of malignancy. Most often colorectal but could be from any GI, lung, breast, or pancreatic primary.
• Above 100 ng/mL: very strongly suggests metastatic disease, classically liver metastases from colorectal cancer.

For surveillance after colorectal cancer surgery, the patient's postoperative nadir is their personal reference. A meaningful rise from that baseline matters more than the absolute number on the page.

The benign list is long and common:

• Smoking. Chronic smokers run CEA roughly 2 to 3 ng/mL higher than non-smokers. Heavy smokers can run substantially higher.
• Inflammatory bowel disease (Crohn's, ulcerative colitis). Active flares raise CEA.
• Diverticulitis, peptic ulcer disease, gastritis.
• Cirrhosis and chronic hepatitis. The liver clears CEA, so hepatic dysfunction raises serum levels.
• Chronic pancreatitis.
• Chronic lung disease, including COPD.
• Hypothyroidism.
• Renal insufficiency.
• Other cancers. Lung, breast, gastric, pancreatic, ovarian, thyroid (medullary in particular). CEA does not specify which organ. Imaging does.

How to read an unexpected CEA elevation:

1. Check smoking status. A CEA of 4.5 ng/mL in a one-pack-a-day smoker is essentially baseline.
2. Check for benign explanations. IBD flare, hepatic dysfunction, recent inflammation.
3. Repeat in 4 to 8 weeks under stable conditions.
4. If persistently elevated above the smoking-adjusted baseline and unexplained, image (CT chest/abdomen/pelvis or PET-CT in the right setting) and review colonoscopy history.
5. Do not start the cancer workup spiral on a single mildly elevated value. Most resolve.

A low CEA is reassuring in two specific contexts: it is consistent with no detectable colorectal cancer, and in a treated colorectal cancer patient it is consistent with remission. There is no clinically meaningful "too low" CEA.

A normal CEA does not rule out colorectal cancer. About 20 to 30 percent of colorectal cancers do not produce CEA, and most stage I cancers have CEA below the cutoff. CEA is not a substitute for colonoscopy. Colonoscopy is the screening test of choice. CEA is for monitoring after a diagnosis.

The single most useful CEA pattern is the post-operative trajectory in a treated colorectal cancer patient.

• After curative resection, CEA should fall into the normal range within 4 to 6 weeks. Failure to normalize predicts residual disease and worse survival.
• A rising CEA on surveillance, even within the "normal" range, is a recurrence signal. NCCN and ASCO both treat a confirmed rise from nadir as cause to image, typically CT chest/abdomen/pelvis, sometimes PET-CT.
• During systemic chemotherapy for metastatic disease, a falling CEA correlates with response and a rising CEA suggests progression. Usually combined with imaging every 2 to 3 months.
• Two consecutive rising values are more meaningful than a single isolated rise. Assay variability and benign factors (a flare, an infection) can move CEA without recurrence.

Outside treated cancer, trend interpretation is less crisp. A drift upward over years in a healthy smoker rarely reflects new malignancy. A sudden new elevation in a non-smoker without explanation deserves scrutiny.

• Confirmed rise from post-operative nadir in a colorectal cancer survivor. Image, even if the absolute value is still in the normal range.
• Failure to normalize CEA within 4 to 6 weeks of curative resection. Suggests residual disease and may influence adjuvant therapy.
• CEA above ~20 ng/mL with no smoking or inflammatory explanation. Workup with cross-sectional imaging.
• CEA above 100 ng/mL. Strongly suggests metastatic disease, classically liver mets.
• Rising CEA on chemotherapy for metastatic disease, combined with imaging, suggests progression.

What does not warrant action: an isolated mildly elevated CEA in a smoker, a one-time elevation during an IBD flare, or a borderline value ordered as part of a "tumor marker panel" without indication. CEA is a monitoring test for known disease. Using it for screening or general reassurance more often produces confusion than clarity.

• Colonoscopy. The actual screening test for colorectal cancer. CEA does not replace it.
• FIT (fecal immunochemical test) or stool DNA testing. Non-invasive screening options with much better evidence than CEA for screening.
• CT chest/abdomen/pelvis. The standard imaging response to a confirmed CEA rise during colorectal cancer surveillance.
• CA 19-9. Sometimes elevated in colorectal cancer alongside CEA; complementary in pancreatic and biliary primaries.
• CA-125. Occasionally relevant when distinguishing primary ovarian cancer from peritoneal metastases of colorectal origin.
• Liver function tests (ALT, AST, alkaline phosphatase, bilirubin). Abnormal results in a colorectal survivor with rising CEA increase concern for liver metastases.